FDA label for Olaparib https://www.azpicentral.com/lynparza_tb/lynparza_tb.pdf#page=1last accessed February 15, 2022.

FDA Approval for Rubraca: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf Last Accessed February 15, 2022.

Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244–50.

Article  CAS  PubMed  Google Scholar 

Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75–87.

Article  CAS  PubMed  Google Scholar 

FDA label for niraparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Last Accessed February 15, 2022.

Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636–48. QUADRA, phase II study of niraparib as treatment in recurrent ovarian cancer

Article  CAS  PubMed  Google Scholar 

Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852–61.

Article  CAS  PubMed  Google Scholar 

Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–64.

Article  CAS  PubMed  Google Scholar 

Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.

Article  CAS  PubMed  Google Scholar 

Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–505. Pivotal phase III randomized control trial of olaparib in newly diagnosed advanced ovarian cancer, demonstrating improved progression-free survival in patients with newly diagnosed advanced ovarian cancer with olaparib maintenance compared with placebo

Article  CAS  PubMed  Google Scholar 

Gonzalez-Martin A, Pothuri B, Vergote I, et al: Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med, 2019 Pivotal phase III randomized control trial of niraparib in newly diagnosed advanced ovarian cancer, demonstrating improved progression-free survival in patients with newly diagnosed advanced ovarian cancer with niraparib maintenance compared with placebo

Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–28. Pivotal phase III randomized control trial of olaparib in combination with bevacizumab in newly diagnosed advanced ovarian cancer, demonstrating improved progression-free survival in patients with newly diagnosed advanced ovarian cancer with olaparib in combination with bevacizumab maintenance compared with placebo

Article  CAS  PubMed  Google Scholar 

Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:1721–31. Five-year survival data on SOLO1, which was a pivotal trial for the olaparib maintenance in the upfront setting

Article  CAS  PubMed  Google Scholar 

Pujade-Lauraine E, Scambia SF, Asselain G, Marme B, Lundemann K, Colombo N, Madry R, Glasspool R, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladie L, Rubo-Perez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A. Maintenance olaparib rechallenge in patients wth ovarian carcinoma previously treated with a PARP inhibitor: Phase IIIB OReO/ENGOT Ov-38 trial. Ann Oncol. 2021;32. https://doi.org/10.1016/j.annonc.2021.08.2110.

Pilie PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin KK, Harrell MI, Oza AM, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9:210–9.

Article  CAS  PubMed  Google Scholar 

Tobalina L, Armenia J, Irving E, et al. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol. 2021;32:103–12.

Article  CAS  PubMed  Google Scholar 

Pettitt SJ, Frankum JR, Punta M, et al. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 2020;10:1475–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zatreanu D, Robinson HMR, Alkhatib O, et al. Poltheta inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun. 2021;12:3636.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Gelot C, Pantelidou C, et al. A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors. Nat Cancer. 2021;2:598–610.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nesic K, Kondrashova O, Hurley RM, et al. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma. Cancer Res. 2021;81:4709–22.

Article  CAS  PubMed  Google Scholar 

Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med. 2019;11(492). https://doi.org/10.1126/scitranslmed.aav4508.

Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, … Bookman MA. Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(19):2138–2147. https://doi.org/10.1200/JCO.21.02011.

Lheureux S, Oaknin A, Garg S, et al. EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin Cancer Res. 2020;26:4206–15.

Article  CAS  PubMed  Google Scholar 

Gabbasov R, Benrubi ID, O’Brien SW, et al. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Cancer Biol Ther. 2019;20:1035–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D'Andrea AD, Gokhale PC, … Shapiro GI. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022;126(7):1027–1036. https://doi.org/10.1038/s41416-021-01664-8.

Rehman FL, Lord CJ, Ashworth A. The promise of combining inhibition of PI3K and PARP as cancer therapy. Cancer Discov. 2012;2:982–4.

Article  CAS  PubMed  Google Scholar 

Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2:1048–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ibrahim YH, Garcia-Garcia C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2:1036–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matulonis UA, Wulf GM, Barry WT, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017;28:512–8.

Article  CAS  PubMed  Google Scholar 

Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20:570–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dias MP, Moser SC, Ganesan S, et al. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18:773–91.

Article  PubMed  Google Scholar 

Yazinski SA, Comaills V, Buisson R, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017;31:318–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murai J, Feng Y, Yu GK, et al. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget. 2016;7:76534–50.

Article  PubMed  PubMed Central  Google Scholar 

Kim H, Xu H, George E, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11:3726.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah PD, Wethington SL, Pagan C, et al. Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2021;163:246–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wethington SL, Shah PD, Martin LP, Tanyi JL, Latif NA, Morgan MA, Torigan DA, Pagan C, Rodiguez D, Domcheck SM, Drapkn R, Shih le-Mng, SMth S, Dean E, Armstrong DK, Gallard S, Simpkns F. Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer. J Clin Oncol. 2021; 39.

Frenel JS KJ, Berton D, Asher R, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pgnata S, Colmbo N, Park-Simon TW, Tamura K, Sonke GS, Loer ES, Freimund AE, Lee CK, Pujade-Lauraine E. Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). J Clin Oncol. 2020;38.

Moore KN, Chambers SK, Hamilton EP, et al. Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm. Phase II study Clin Cancer Res. 2022;28:36–44.

Article  CAS  PubMed  Google Scholar 

Oza AM, Estevez-Diz M, Grischke EM, et al. A biomarker-enriched, randomized phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin Cancer Res. 2020;26:4767–76.